Surrozen (NASDAQ:SRZN) Major Shareholder Tcg Crossover Gp Ii, Llc Purchases 17,763 Shares

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc purchased 17,763 shares of the business’s stock in a transaction on Wednesday, February 11th. The shares were acquired at an average price of $23.57 per share, for a total transaction of $418,673.91. Following the completion of the acquisition, the insider directly owned 650,567 shares in the company, valued at approximately $15,333,864.19. This represents a 2.81% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Thursday, February 12th, Tcg Crossover Gp Ii, Llc acquired 1,093 shares of Surrozen stock. The stock was bought at an average price of $23.86 per share, with a total value of $26,078.98.
• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc bought 4,355 shares of Surrozen stock. The shares were bought at an average price of $21.94 per share, for a total transaction of $95,548.70.
• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc bought 731 shares of Surrozen stock. The shares were bought at an average cost of $21.38 per share, for a total transaction of $15,628.78.
• On Friday, January 30th, Tcg Crossover Gp Ii, Llc purchased 4,271 shares of Surrozen stock. The stock was bought at an average price of $21.39 per share, with a total value of $91,356.69.

Surrozen Trading Down 1.4%

Shares of NASDAQ SRZN opened at $24.48 on Friday. The firm has a market capitalization of $209.79 million, a P/E ratio of -1.10 and a beta of 0.58. The firm’s 50-day moving average price is $21.59 and its 200-day moving average price is $15.75. Surrozen, Inc. has a 1-year low of $5.90 and a 1-year high of $25.84.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a report on Thursday, January 22nd. Lifesci Capital upgraded shares of Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Finally, Wall Street Zen upgraded shares of Surrozen to a “sell” rating in a report on Friday, November 28th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $32.00.

Institutional Trading of Surrozen

A number of institutional investors and hedge funds have recently modified their holdings of SRZN. China Universal Asset Management Co. Ltd. lifted its holdings in Surrozen by 50.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock worth $34,000 after acquiring an additional 500 shares during the period. Citadel Advisors LLC increased its position in shares of Surrozen by 32.8% during the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after purchasing an additional 3,424 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Surrozen during the 4th quarter worth $247,000. Geode Capital Management LLC boosted its holdings in shares of Surrozen by 22.6% in the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after buying an additional 5,702 shares during the last quarter. Finally, Ieq Capital LLC purchased a new position in shares of Surrozen in the 4th quarter worth about $304,000. 66.57% of the stock is owned by hedge funds and other institutional investors.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.